SNGX
Soligenix, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.38
−0.84%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | 250.0K |
| Cost of Revenue | 2.1K | — | 119.4K | 742.0K | 550.8K |
| Gross Profit | (2.1K) | — | (119.4K) | (742.0K) | (300.8K) |
| Operating Expenses | |||||
| R&D Expense | 6.6M | 7.5M | 5.2M | 3.3M | 7.9M |
| SG&A Expense | 4.4M | 4.4M | 4.2M | 4.5M | 6.7M |
| General & Admin Expense | 4.4M | 4.4M | 4.2M | 4.5M | 6.7M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | (119.4K) | (839.4K) | (698.9K) |
| Total Operating Expenses | 11.0M | 11.8M | 9.3M | 7.0M | 13.9M |
| Cost and Expenses | 11.0M | 11.8M | 9.4M | 7.7M | 14.5M |
| Operating Income (EBIT) | (11.0M) | (11.8M) | (9.4M) | (7.7M) | (14.2M) |
| Non-Operating | |||||
| Interest Income | 21.5K | 270.2K | 214.0K | — | — |
| Interest Expense | — | — | — | 49.1K | 822.6K |
| Net Interest Income | 21.5K | 270.2K | 214.0K | (49.1K) | (822.6K) |
| Other Non-Op Income/Expense | 293.3K | 258.5K | 763.8K | (210.6K) | (714.4K) |
| Non-Operating Income (excl Interest) | (122.7K) | (258.5K) | 25.5K | (23.8K) | (108.2K) |
| EBT (Pre-Tax Income) | (10.7M) | (11.6M) | (8.7M) | (7.9M) | (15.0M) |
| Income Tax Expense | (506.6K) | (506.6K) | (409.1K) | (1.8M) | (1.2M) |
| Bottom Line | |||||
| Net Income | (10.2M) | (11.1M) | (8.3M) | (6.1M) | (13.8M) |
| Earnings from Cont. Ops | (10.2M) | (11.1M) | (8.3M) | (6.1M) | (13.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (10.2M) | (11.1M) | (8.3M) | (6.1M) | (13.8M) |
| Per Share | |||||
| Basic EPS | ($1.27) | ($2.14) | ($4.98) | ($12.66) | ($76.96) |
| Diluted EPS | ($1.27) | ($2.14) | ($4.98) | ($12.66) | ($76.89) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $1.39 |
| Shares | |||||
| Basic Shares Outstanding | 16.0M | 5.2M | 1.7M | 484877 | 179292 |
| Diluted Shares Outstanding | 16.0M | 5.2M | 1.7M | 484877 | 179459 |
| Profitability Metrics | |||||
| EBITDA | (10.9M) | (11.6M) | (9.5M) | (7.7M) | (14.1M) |
| D&A | 3.0K | 3.2K | 5.8K | 6.6K | 24.6K |
| EBIT | (10.9M) | (11.6M) | (9.5M) | (7.7M) | (14.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026